COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03778931
Recruitment Status : Active, not recruiting
First Posted : December 19, 2018
Last Update Posted : October 19, 2020
Information provided by (Responsible Party):
Radius Pharmaceuticals, Inc.

Brief Summary:
This Phase 3 clinical study compares the efficacy and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6 inhibitor in combination with fulvestrant or an aromatase inhibitor (AI) .

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Elacestrant Drug: Standard of Care Phase 3

Detailed Description:
This is an international, multicenter, randomized, open-label, active-controlled, event-driven, Phase 3 clinical study comparing the efficacy and safety of elacestrant to the SoC options of fulvestrant or an aromatase inhibitor (AI) in postmenopausal women and in men with advanced or metastatic ER+/HER2- breast cancer, either in subjects with tumors that harbor mutations in the ligand binding domain (LBD) of the estrogen receptor 1 (ESR1) gene (ESR1-mut subjects) or in all subjects regardless of ESR1 status (ESR1-mut and ESR1 wild type [ESR1-WT]) and whose disease has relapsed or progressed on at least one and no more than two prior lines of endocrine therapy (with documented progression), which must have included prior CDK4/6 inhibitor therapy in combination with fulvestrant or an aromatase inhibitor (AI) and for whom hormonal monotherapy with one of the SoC drugs (fulvestrant, anastrozole, letrozole, exemestane) is an appropriate treatment option.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 466 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Actual Study Start Date : May 10, 2019
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : August 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Elacestrant
Subjects in Arm 1 will receive elacestrant
Drug: Elacestrant
400 mg/day once daily oral dosing
Other Name: RAD1901

Active Comparator: Standard of Care (SoC)
Subjects in Arm 2 will receive Investigator's choice of one of the Standard of Care drugs (fulvestrant, anastrozole, letrozole, or exemestane)
Drug: Standard of Care
  • Fulvestrant: 500 mg administered intramuscularly (IM) into the buttocks as two 5 mL injections on C1D1, C1D15 and C2D1 and Day 1 of every subsequent 28-day cycle
  • Anastrozole 1 mg/day on a continuous dosing schedule
  • Letrozole: 2.5 mg/day on a continuous dosing schedule
  • Exemestane: 25 mg/day on a continuous dosing schedule
Other Name: Faslodex, Arimidex, Femara, Aromasin

Primary Outcome Measures :
  1. Progression Free Survival (PFS) in the ESR1-mut subjects [ Time Frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months) ]
    Progression Free Survival (PFS) based on blinded IRC assessment in the ESR1-mut subjects

  2. PFS in all (ESR1-mut and ESR1-WT) subjects [ Time Frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months) ]
    PFS based on blinded Imaging Review Committee (IRC) assessment in all (ESR1-mut and ESR1-WT) subjects

Secondary Outcome Measures :
  1. Objective Survival (OS) in ESR1-mut subjects [ Time Frame: From Date of Randomization until Death Due to Any Cause (Estimated up to 24 Months) ]
    OS in ESR1-mut subjects, where OS is defined as the length of time from randomization until the date of death from any cause

  2. OS in all (ESR1-mut and ESR1-WT) subjects [ Time Frame: From Date of Randomization until Death Due to Any Cause (Estimated up to 24 Months) ]
    OS in all (ESR1-mut and ESR1-WT) subjects

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Critical Inclusion Criteria:

  1. Subjects with proven diagnosis of adenocarcinoma of the breast with evidence of either locally advanced disease not amenable to resection or radiation therapy with curative intent or metastatic disease not amenable to curative therapy.
  2. Subjects must be appropriate candidates for endocrine monotherapy
  3. Subjects must have measurable disease or, nonmeasurable (evaluable) bone-only disease
  4. Female or male subjects age ≥ 18 years; female subjects must be postmenopausal women and male subjects must not allow pregnancy with their sperm (abstain, do not donate sperm, etc).
  5. Subjects must have ER+/HER2-tumor status
  6. Subjects must have previously received at least one and no more than two lines of endocrine therapy for advanced/metastatic breast cancer and meet additional previous treatment criteria.
  7. Subjects must have received prior treatment with a CDK4/6 inhibitor in combination with either fulvestrant or an aromatase inhibitor (AI).
  8. Subjects may have received no more than one line of chemotherapy in the advanced/metastatic setting.
  9. Subjects must have ctDNA ESR1-mut or ESR1-WT status as determined by central testing before subject is randomized.

Critical Exclusion Criteria:

  1. Prior treatment with elacestrant, GDC-0810, GDC-0927, GDC-9545, LSZ102, AZD9496, bazedoxifene, or other investigational SERD or investigational ER antagonist.
  2. Prior anticancer or investigational drug treatment within the following windows:

    1. Fulvestrant treatment < 28 days before first dose of study drug
    2. Any endocrine therapy < 14 days before first dose of study drug (with the exception of GnRH agonist therapy in male subjects)
    3. Chemotherapy < 21 days before first dose of study drug
    4. Any investigational anti-cancer drug therapy < 28 days or five half-lives (whichever is shorter) before the first dose of study drug. Enrollment of subjects whose most recent therapy was an investigational agent should be discussed with the Sponsor
  3. Presence of symptomatic visceral disease as defined in protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03778931

Hide Hide 185 study locations
Layout table for location information
United States, Arizona
The University of Arizona Cancer Center
Tucson, Arizona, United States, 85724
United States, Arkansas
St. Bernards Medical Center
Jonesboro, Arkansas, United States, 72401
United States, California
St. Jude Heritage Healthcare
Fullerton, California, United States, 92835
Adventist Health Glendale
Glendale, California, United States, 91206
Keck Hospital of USC-Norris Healthcare (HC3), Investigational Drug Service (IDS)
Los Angeles, California, United States, 90033
USC IDS Pharmacy
Los Angeles, California, United States, 90033
Ridley Tree Cancer Center
Los Angeles, California, United States, 90095
UCLA Hematology/Oncology
Los Angeles, California, United States, 90095
UCLA West Medical Pharmacy 159
Los Angeles, California, United States, 90095
TMPN Cancer Care
Redondo Beach, California, United States, 90277
UC Davis Medical Center, Investigational Drug Service
Sacramento, California, United States, 95817
Central Coastal Medical Oncology
Santa Maria, California, United States, 93454
United States, Colorado
University of Colorado Hospital - Cancer Center
Aurora, Colorado, United States, 80045
US Oncology - Rocky Mountain Cancer Centers - Midtown
Denver, Colorado, United States, 80218
Poudre Valley Health Care, Inc. d/b/a Poudre Valley Health System
Fort Collins, Colorado, United States, 80528
United States, District of Columbia
MedStar Washington Hospital Center
Washington, District of Columbia, United States, 20010
United States, Florida
UF Health Cancer Center at Orlando Health
Orlando, Florida, United States, 32806
Moffitt Cancer Center
Tampa, Florida, United States, 33612
United States, Georgia
Piedmont Cancer Institute, P.C. - Oncology
Atlanta, Georgia, United States, 30318
Suburban Hematology-Oncology Associates
Lawrenceville, Georgia, United States, 30046
United States, Illinois
Chicago Association for Research and Education in Science
Chicago, Illinois, United States, 60141
Rush University Cancer Center
Chicago, Illinois, United States, 60612
Healthcare Research Network II
Tinley Park, Illinois, United States, 60487
United States, Kentucky
Norton Cancer Institute
Louisville, Kentucky, United States, 40207
Pikeville Medical Center - Oncology/Hematology
Pikeville, Kentucky, United States, 41501
United States, Louisiana
Ochsner Cancer Institute
New Orleans, Louisiana, United States, 70121
United States, Maine
New England Cancer Specialists
Scarborough, Maine, United States, 04074
United States, Maryland
Mercy Medical Center
Baltimore, Maryland, United States, 21202
Maryland Oncology Hematology,
Frederick, Maryland, United States, 21702
United States, Massachusetts
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States, 02114
Mass General Cancer Center at Newton Wellesley - Oncology
Boston, Massachusetts, United States, 02462
Mass General North Shore Cancer Center - Oncology
Danvers, Massachusetts, United States, 01923
United States, Michigan
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, Minnesota
Minnesota Oncology
Minneapolis, Minnesota, United States, 55404
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Mississippi
Jackson Oncology Associates, PLLC.
Jackson, Mississippi, United States, 39202
United States, New Jersey
Precision Cancer Research
Freehold, New Jersey, United States, 07728
Saint Barnabas Medical Center - Cancer Center
Livingston, New Jersey, United States, 07039
United States, New Mexico
New Mexico Oncology Hematology Consultants - Oncology
Albuquerque, New Mexico, United States, 87109
New Mexico Cancer Care Alliance
Albuquerque, New Mexico, United States, 87131
United States, New York
Montefiore Medical Center
Bronx, New York, United States, 10461
New York University Clinical Cancer Center
New York, New York, United States, 10016
Stony Brook University
Stony Brook, New York, United States, 11794
United States, Ohio
Oncology Hematology Care Inc.
Cincinnati, Ohio, United States, 45211
University Hospitals of Cleveland
Cleveland, Ohio, United States, 44106
Toledo Clinic Cancer Center - Toledo
Toledo, Ohio, United States, 43623
United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States, 97239
United States, Pennsylvania
Pinnacle Health Cancer Institute
Harrisburg, Pennsylvania, United States, 17109
Paoli Hospital
Paoli, Pennsylvania, United States, 19301
Abington Hematology Oncology Associates
Willow Grove, Pennsylvania, United States, 19090
Lankenau Medical Center
Wynnewood, Pennsylvania, United States, 19096
United States, Tennessee
West Cancer Center
Germantown, Tennessee, United States, 38138
Brig Center For Cancer Care And Survivorship
Knoxville, Tennessee, United States, 37909
United States, Texas
Texas Oncology - Central Austin Cancer Center
Austin, Texas, United States, 78731
TX Oncology Dallas Center
Dallas, Texas, United States, 75203
Medical City Dallas Hospital
Dallas, Texas, United States, 75230
Dallas Presbyterian Hospital - Texas Oncology PA
Dallas, Texas, United States, 75231
Texas Oncology - Willowbrook
Houston, Texas, United States, 77070
US Oncology Research-- Investigational Product Center
Irving, Texas, United States, 75063
Texas Oncology - McAllen
McAllen, Texas, United States, 78053
Texas Oncology, P.A.
Paris, Texas, United States, 75460
Texas Oncology - North Texas Regional Cancer Center
Plano, Texas, United States, 75075
Texas Oncology, P.A.
Plano, Texas, United States, 75093
Cancer Therapy and Research Center at UTHSCSA
San Antonio, Texas, United States, 78229
Texas Oncology - The Woodlands, Gynecologic Oncology
The Woodlands, Texas, United States, 77380
Renovatio Clinical
The Woodlands, Texas, United States, 77389
USO Texas Oncology - Tyler
Tyler, Texas, United States, 75702
United States, Utah
Utah Cancer Specialists
Salt Lake City, Utah, United States, 84124
United States, Virginia
University of Virginia Cancer Center
Charlottesville, Virginia, United States, 22908
Inova Schar Cancer Institute
Fairfax, Virginia, United States, 22031
Fort Belvoir Community Hospital
Fort Belvoir, Virginia, United States, 22060
United States, Washington
Benaroya Research Institute at Virginia Mason
Seattle, Washington, United States, 98101
Centro Médico Austral
Buenos Aires, Ciudad Autónoma De Buenos Aire, Argentina, 1019
Fundacion CENIT para la Investigación en Neurociencias - Clinic
Ciudad Autonoma de Buenos Aire, Argentina, C1025ABI
Clínica Universitaria Reina Fabiola
Córdoba, Argentina, 5004
Fundación CORI
La Rioja, Argentina, 5300
Sunshine Coast University Hospital
Birtinya, Australia, 4575
Macarthur Cancer Therapy
Campbelltown, Australia, 2560
St Vincent's Hospital Melbourne
Fitzroy, Australia, 3065
Klinikum Wels-Grieskirchen GmbH
Wels, Oberösterreich, Austria, 4600
Landeskrankenhaus (LKH) Leoben-Eisenerz
Leoben, Steiermark, Austria, 8700
Universitätsklinik Innsbruck
Innsbruck, Tirol, Austria, 6020
AZ Klina
Brasschaat, Antwerpen, Belgium, 2930
UZ Antwerpen - Oncologie
Edegem, Antwerpen, Belgium, 2650
AZ Turnhout
Turnhout, Antwerpen, Belgium, 2300
Institut Jules Bordet - Oncologie Médicale
Brussels, Brussels Capital Region, Belgium, 1000
UZ Brussel - Campus Jette
Brussel, Brussels Capital Region, Belgium, 1090
CHU Brugmann
Bruxelles, Brussels Capital Region, Belgium, 1020
Cliniques Universitaires Saint-Luc - Oncology
Bruxelles, Brussels Capital Region, Belgium, 1200
Grand Hôpital de Charleroi - Site Notre-Dame
Charleroi, Hainaut, Belgium, 6000
INDC Entité Jolimontoise - CH de Jolimont-Lobbes
Haine-Saint-Paul, Hainaut, Belgium, 7100
Centre Hospitalier de l'Ardenne - Site de Libramont
Libramont, Luxembourg, Belgium, 6800
Onze-Lieve-Vrouwziekenhuis Aalst
Aalst, Oost-Vlaanderen, Belgium, 9300
AZ Nikolaas - Campus Sint-Niklaas Moerland
Sint-Niklaas, Oost-Vlaanderen, Belgium, 9100
Universitaire Ziekenhuizen (UZ) - Leuven Cancer Institute
Leuven, Vlaams Brabant, Belgium, 3000
AZ Sint-Jan Brugge - Oostende AV - Campus Sint-Jan - Oncology
Brugge, West-Vlaanderen, Belgium, 8000
AZ Groeninge
Kortrijk, West-Vlaanderen, Belgium, 8500
AZ Groeninge - Campus Kennedylaan
Kortrijk, Belgium, 8500
CHU UCL Namur - Site Sainte-Elisabeth
Namur, Belgium, 5000
CHU UCL Namur Campus Sainte-Elisabeth
Namur, Belgium, 5000
Clinique Saint Pierre
Ottignies, Belgium, 1340
Canada, Quebec
Pharmacie du CRCHUM
Montreal, Quebec, Canada, H2X 1R9
McGill University Health Centre - Cedars Cancer Center - Oncology
Montreal, Quebec, Canada, H4A-3J1
CHU de Quebec - Hopital du Saint Sacrement
Québec, Canada, G1S 4L8
Vejle Sygehus
Vejle, South Denmark, Denmark, 7100
Næstved Sygehus
Næstved, Zeeland, Denmark, 4700
Aalborg Universitetshospital
Aalborg, Denmark, 9100
Odense Universitetshospital - Oncology
Odense, Denmark, 5000
Centre de Lutte Contre le Cancer (CLCC)
Caen, Calvados, France, 14076
Hopital Trousseau - Service d'oncologie médicale
Tours, Indre-et-Loire, France, 37044
Centre Jean Perrin
Clermont Ferrand, Puy-de-Dôme, France, 63011
Centre François Baclesse Service Pharmacie
Caen, France, 14076
Centre Georges Francois Leclerc
Dijon, France, 21079
Hôpital Privé Jean Mermoz Département Pharmacie
Lyon, France, 69008
"Institut régional du Cancer Montpellier Service pharmacie-Essais cliniques"
Montpellier, France, 34298
Centre De Lutte Contre Le Cancer - Institut Curie - Département d'Oncologie Médica
Paris, France, 75005
Hôpital René Huguenin - Institut Curie - Oncologie médicale
Saint-Cloud, France, 92210
"Institut de Cancérologie Lucien Neuwirth Service pharmacie-Essais cliniques"
Saint-Priest-en-Jarez, France, 42270
IUCT-Oncopole Pharmacie-Essais Cliniques
Toulouse, France, 31100
University General Hospital Of Patras - Dpt Of Medicine, Division Oncology
Patra, Achaïa, Greece, 26504
Metropolitan Hospital - Oncology Unit
Athens, Attiki, Greece, 18547
University General Hospital of Larissa
Larissa, Larisa, Greece, 41110
Bioclinic Thessaloniki
Thessaloniki, Greece, 54622
Pécsi Tudományegyetem Klinikai Központ
Pécs, Baranya, Hungary, 7623
Bács-Kiskun Megyei Kórház
Debrecen, Hajdú-Bihar, Hungary, 4032
Debreceni Egyetem Klinikai Központ
Debrecen, Hajdú-Bihar, Hungary, 7032
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz - Rendeloint
Szolnok, Jász-Nagykun-Szolnok, Hungary, 5004
Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókór
Nyiregyhaza, Szabolcs-Szatmár-Bereg, Hungary, 4400
Uzsoki Utcai Kórház
Budapest, Hungary, 1145
Semmelweis Egyetem, Onkológiai Központ,
Budapest, Hungary, H-1083
Országos Onkológiai Intézet
Budapest, Hungary, H-1122
Bon Secours Hospital [Oncology]
Cork City, Ireland
St Vincent's University Hospital
Dublin, Ireland
Clinical Research Facility, St. James's Hospital
Sligo, Ireland, F91 H684
Pharmacy Aseptic Compounding Unit Level 4, Sligo University Hospital
Sligo, Ireland, F91 H684
Sligo University Hospital
Sligo, Ireland, F91 H684
Pharmacy, UHW
Waterford, Ireland, X91 ER8E
Shaare Zedek Medical center
Jerusalem, Israel, 9103102
Hadassah MO - Oncology,Hadassah MO
Jerusalem, Israel, 9112001
Meir Medical Center
Kfar-Saba, Israel, 4428164
Galilee Medical Center
Nahariya, Israel, 2210001
Rabin Medical Center - Beilinson Hospital - Davidoff Cancer
Petah Tikva, Israel, 4941492
Tel Aviv Sourasky Medical Center - Oncology
Tel-Aviv, Israel, 6423906
The Chaim Sheba Medical Center
Tel-Hashomer, Israel, 5265601
Assaf Harofeh Medical Center
Zerifin, Israel, 7030000
Policlinico S.Orsola Malpighi, AOU di Bologna - SSD Oncol.Med. Addarii-Zamagni
Bologna, Italy, 40138
PO di Cremona, ASST di Cremona - Patologia Mammaria e Breast Unit - Cremona
Cremona, Italy, 26100
DiMI, Dipartimento di Medicina interna e Specialità mediche,
Genova, Italy, 16132
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, Italy, 47014
Azienda Ospedaliero-Universitaria Policlinico di Modena
Modena, Italy, 41100
Ospedale San Gerardo-ASST Monza
Monza, Italy, 20900
AOU Maggiore della Carità - SC Oncologia
Novara, Italy, 28100
Azienda Ospedaliero-Universitaria di Parma
Parma, Italy, 43126
IRCCS Policlinico San Matteo
Pavia, Italy, 27100
SO S.Chiara, AOU Pisana - Oncologia 2
Pisa, Italy, 56126
Policlinico Universitario Campus Bio-medico, Università Campus Bio-medico di Roma,
Roma, Italy, 00128
Policlinico A. Gemelli
Roma, Italy, 00168
Azienda Sanitaria Universitaria Integrata di Udine
Udine, Italy, 33100
Korea, Republic of
National Cancer Center
Goyang, Korea, Republic of, 10408
Gachon University Gil Medical Center
Incheon, Korea, Republic of, 21565
Seoul National University Bundang Hospital
Seongnam-si, Korea, Republic of, 13620
Korea University Anam Hospital
Seoul, Korea, Republic of, 02841
Seoul National University Hospital
Seoul, Korea, Republic of, 03080
Severance Hospital, Yonsei University Health System
Seoul, Korea, Republic of, 03722
Asan Medical Center
Seoul, Korea, Republic of, 05505
Samsung Medical Center
Seoul, Korea, Republic of, 06351
Instituto Português de Oncologia de Coimbra
Coimbra, Portugal, 3000-075
Hospital Senhora da Oliveira - Guimarães, E.P.E.
Guimarães, Portugal, 4835-044
Hospital da Luz
Lisboa, Portugal, 1500-650
Instituto Português Oncologia Francisco Gentil do Porto
Porto, Portugal, 4200-072
Hospital General Universitario de Elche
Elche, Alicante, Spain, 03202
Hospital Universitario Virgen del Rocio
Sevilla, Andalucía, Spain, 41013
Hospital Universitario de Canarias
Tenerife, Canarias, Spain, 38320
Hospital de Navarra
Pamplona, Navarra, Spain, 31008
Hospital Xeral Álvaro Cunqueiro
Vigo, Pontevedra, Spain, 36312
Hospital Clinic de Barcelona
Barcelona, Spain, 08036
IOB Ruber Internacional
Madrid, Spain, 28034
Hospital Clínico San Carlos
Madrid, Spain, 28040
Hospital Universitario La Paz
Madrid, Spain, 28046
Hospital Universitario Virgen de la Macarena
Sevilla, Spain, 41009
Hospital Clínico Universitario de Valencia
Valencia, Spain, 46010
United Kingdom
Velindre Cancer Centre - Oncology
Cardiff, United Kingdom, CF14 2TL
University College London Hospitals
London, United Kingdom, NW1 2PG
Sarah Cannon Research Institute
London, United Kingdom, W1G 6AD
Taunton and Somerset NHS Trust
Taunton, United Kingdom, TA1 5DA
Sponsors and Collaborators
Radius Pharmaceuticals, Inc.
Layout table for investigator information
Study Director: Sr. Director, Clinical Operations Radius Health, Inc.
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Radius Pharmaceuticals, Inc. Identifier: NCT03778931    
Other Study ID Numbers: RAD1901-308
First Posted: December 19, 2018    Key Record Dates
Last Update Posted: October 19, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Estrogen Receptor Antagonists